A trial looking at ponatinib for people with newly diagnosed chronic myeloid leukaemia (EPIC)

Cancer type:

Blood cancers
Chronic leukaemia
Chronic myeloid leukaemia (CML)
Leukaemia

Status:

Results

Phase:

Phase 3

This trial was looking at ponatinib for people with newly diagnosed chronic myeloid leukaemia (CML) that is Philadelphia chromosome positive. It was for people whose CML was stable and developing slowly (chronic phase).

Most people with CML have a change (mutation Open a glossary item) to a gene. Doctors call this being Philadelphia positive. It affects a protein called BCR-ABL, which signals to the body to make too many white blood cells.

The main treatment for CML is imatinib. Imatinib is a biological therapy called a cancer growth blocker. It blocks the signals that cancer cells use to divide and grow.

Ponatinib is also a biological therapy that is a cancer growth blocker. It works in a very similar way to imatinib.

We knew from research that ponatinib could work for people with CML that had come back while having treatment with other cancer growth blockers, or after having had treatment with them. The researchers thought that it may work well for newly diagnosed people who had not had treatment.  

The aims of this trial were to find out

  • How well ponatinib works for newly diagnosed people with CML
  • How safe ponatinib is for these people
  • How ponatinib affects their quality of life Open a glossary item

Summary of results

This trial was stopped early. The UK trial team have told us they don’t expect there to be results available.

 

Recruitment start:

Recruitment end:

How to join a clinical trial

Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Chief Investigator

Professor Richard Clark

Supported by

ARIAD Pharmaceuticals Inc
NIHR Clinical Research Network: Cancer

If you have questions about the trial please contact our cancer information nurses

Freephone 0808 800 4040

Last review date

CRUK internal database number:

Oracle 10191

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Last reviewed:

Rate this page:

No votes yet
Thank you!
We've recently made some changes to the site, tell us what you think